Changes in Glucose and Cholesterol Level in Schizophrenic Patients Treated with Atypical Antipsychotics or with Valproate Combination.
- Author:
Doug Hyun HAN
1
;
Jung Hyun LEE
;
Tae Hun KIM
;
Jung Eun CHOI
;
Doo Byung PARK
;
Baik Seok KEE
Author Information
1. Department of Psychiatry, Chun-Cheon National Hospital, Chuncheon, Korea.
- Publication Type:Original Article
- Keywords:
Glucose;
Cholesterol;
Weight gain;
Antipsychotics;
Sodium valproate
- MeSH:
Antipsychotic Agents*;
Body Image;
Body Mass Index;
Cholesterol*;
Compliance;
Diabetes Mellitus;
Follow-Up Studies;
Glucose*;
Haloperidol;
Humans;
Obesity;
Risperidone;
Valproic Acid*;
Weight Gain
- From:Korean Journal of Psychopharmacology
2004;15(2):211-218
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The association of obesity, diabetes mellitus, drug compliance, and body image with use of antipsychotic medication has been documented in many studies. We aimed to assess the effects of antipsychotics and sodium valproate combination therapy on glucose, cholesterol level and weight in schizophrenic patients. METHODS: Chronic schizophrenic patients were grouped according to drug combination: risperidone, olanzapine, haloperidol, risperidone+valproic acid (VP), olanzapine+VP, haloperidol+VP. Planned assessment of included glucose and cholesterol, which were collected at baseline and at the end of the 12 weeks later. RESULTS: There were significantly increased glucose and cholesterol level, in olanzapine+VP group, but not in risperidone group. Cholesterol levels were not increased at the end of 12 weeks for haloperidol and risperidone group. Glucose and cholesterol levels had no significant association with weight gain. CONCLUSION: Changes in glucose and cholesterol level, weight, and body mass index associated with antipsychotics including sodium valproate combination were reported in our report. In the future, we need follow up study and various studies about other combination drug and metabolic symptoms.
